The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
HAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)63946-8 · Cited by 679
HAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · The Journal of Urology · doi:10.1097/00005392-200302000-00018 · Cited by 638
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M. J., Rotman, M., Jones, C., Asbell, S. O., Valicenti, R. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.004 · Cited by 637
Cimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Jager, G. J., Barentsz, J. O., Oosterhof, G. O., Witjes, J. A., & Ruijs, S. J. (1996) · American Journal of Roentgenology · doi:10.2214/ajr.167.6.8956585 · Cited by 259
Hofer, C., Laubenbacher, C., Block, T., Breul, J., Härtung, R., & Schwaiger, M. (1999) · European Urology · doi:10.1159/000019923 · Cited by 252
Self-citationRoberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M., & Zincke, H. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62406-3 · Cited by 252
Han, M., Partin, A. W., ZAHURAK, M. L., Piantadosi, S., Epstein, J. I., & Walsh, P. C. (2003) · PubMed · doi:10.1097/01.ju.0000045749.90353.c7 · Cited by 246
Cited by
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Self-citationCurrent use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Self-citationUmbehr, M. H., Müntener, M., Hany, T., Sulser, T., & Bachmann, L. M. (2013) · European Urology · doi:10.1016/j.eururo.2013.04.019 · Cited by 354
Plathow, C., & Weber, W. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045930 · Cited by 328
Herlemann, A., Wenter, V., Kretschmer, A., Thierfelder, K. M., Bartenstein, P., Faber, C., Gildehaus, F.-J., Stief, C. G., Gratzke, C., & Fendler, W. P. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.051 · Cited by 295
Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
Jadvar, H. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077941 · Cited by 290
Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P. M., & Rubello, D. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182867f3c · Cited by 278
Giovacchini, G., Picchio, M., Coradeschi, E., Bettinardi, V., Gianolli, L., Scattoni, V., Cozzarini, C., Di Muzio, N., Rigatti, P., Fazio, F., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1253-3 · Cited by 270
Schwenck, J., Rempp, H., Reischl, G., Kruck, S., Stenzl, A., Nikolaou, K., Pfannenberg, C., & la Fougère, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3490-6 · Cited by 269
68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016) · Cancer Imaging · doi:10.1186/s40644-016-0072-6 · Cited by 208
“Especially in patients with prostate-specific antigen (PSA)values below 3 ng/ml the detection rate is reported to be only 40–60 % [9–11].”
BackgroundSelf-citationPicchio, M., Briganti, A., Fanti, S., Heidenreich, A., Krause, B. J., Messa, C., Montorsi, F., Reske, S. N., & Thalmann, G. N. (2011) · European Urology · doi:10.1016/j.eururo.2010.09.004 · Cited by 190
“It has been shown that choline PET detection rates rise with increasing PSA values [4,8,10,11,24,28,31].”
BackgroundInfluentialSelf-citationFonti, R., Conson, M., & Del Vecchio, S. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.001 · Cited by 153
Choline intake and risk of lethal prostate cancer: incidence and survival
Richman, E. L., Kenfield, S. A., Stampfer, M. J., Giovannucci, E. L., Zeisel, S. H., Willett, W. C., & Chan, J. M. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.039784 · Cited by 75
“Because of the selective and high uptake of circulating choline by prostate cancer cells, radiolabeled choline is used to identify prostate cancer recurrence and metastases (22, 23), and patients with high-grade prostate cancers have higher concentrations of choline-containing compounds than do those with low-grade pr…”
Background
Metadata
- Authors
- Krause, B. J., Souvatzoglou, M., Tuncel, M., Herrmann, K., Buck, A. K., Praus, C., Schuster, T., Geinitz, H., Treiber, U., & Schwaiger, M.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2007-09-22
- Volume
- 35
- Issue
- 1
- Pages
- 18-23
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W1990235169
- Cited by
- 367
- References
- 21
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.